Skip to content
value.today

TFF Pharmaceuticals, Inc.

🇺🇸 Austin, Texas, USAPharmaceuticalsFounded 2018
Total raised
$48 M
3 rounds on record
Latest round
$26 M
Aug 2020
First round on record
Mar 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TFF Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$26 MNo. 3$10 to $50 million

TFF Pharmaceuticals, Inc.: Raise no. 3, Aug 2020

Investors in this round

23 investors had bought by the notice of Aug 19, 2020: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for TFF Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,554,814
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian S. Windsor · Executive Officer, Director
  • Glenn S. Mattes · Executive Officer, Director
  • Kirk S. Coleman · Executive Officer
  • Aaron S. Fletcher · Director
  • Harlan S. Weisman · Director
  • Malcolm S. Fairbairn · Director
  • Randy S. Thurman · Director
  • Robert S. Mills, Jr. · Director
  • Stephen S. Rocamboli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in CA, CT, NC, NY, TX, WA

Signed by Kirk Coleman, Chief financial officer. Source: SEC Form D, newest notice filed Aug 19, 2020. Read the notice at the SEC.

equitySEC
May 2019$8 MNo. 2$2 to $10 million

TFF Pharmaceuticals, Inc.: Raise no. 2, May 2019

Investors in this round

229 investors had bought by the notice of Jul 24, 2019: 229 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for TFF Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$817,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Glenn S. Mattes · Executive Officer, Director
  • Kirk S. Coleman · Executive Officer
  • Aaron S. Fletcher · Director
  • Brian S. Windsor · Director
  • Harlan S. Weisman · Director
  • Randy S. Thurman · Director
  • Robert S. Mills, Jr. · Director
  • Stephen S. Rocamboli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • NATIONAL SECURITIES CORPORATION (CRD 7569) · Seattle, WashingtonSold in AR, CA, CO, CT, DC, FL, GA, IA, IL, MA, MD, MI, MN, MO, NC, NJ, NV, NY, OK, PA, TX, VA, WA, WI

Remarks in the notice

  • On fees: “Represents 10% of the gross proceeds. The placement agent also received a warrant to purchase 10% of the number of shares of Series A Preferred Stock issued in the offering.”

Signed by Kirk Coleman, Chief financial officer. Source: SEC Form D, newest notice filed Jul 24, 2019. Read the notice at the SEC.

equitySEC
Mar 2018$14 MNo. 1$10 to $50 million

TFF Pharmaceuticals, Inc.: Raise no. 1, Mar 2018

Investors in this round

224 investors had bought by the notice of Mar 27, 2018: 224 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for TFF Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $14 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,415,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian S. Windsor · Executive Officer, Director
  • Kirk S. Coleman · Executive Officer
  • Robert S. Mills, Jr. · Executive Officer, Director
  • Aaron S. Fletcher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • National Securities Corporation (CRD 7569) · Seattle, WashingtonSold in AR, AZ, CA, CO, CT, DC, FL, GA, IL, IN, MA, MD, MI, MN, NC, NJ, NV, NY, OK, PA, TX, UT, VA, WA, WI

Remarks in the notice

  • On fees: “Represents 10% of the gross proceeds. The placement agent also received a warrant to purchase 10% of the number of shares of Series A Preferred Stock issued in the offering.”

Signed by Kirk Coleman, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 27, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TFF Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).

    SEC Form D · Aug 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2020

That is all the official record says: TFF Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in TFF Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Aaron G.l. FletcherPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2019)SEC Form 3
Robert S. MillsPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 229 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TFF Pharmaceuticals, Inc.
NameRoleNamed in
Brian S. WindsorExecutive officerAug 2020
Glenn S. MattesExecutive officerAug 2020
Kirk S. ColemanExecutive officerAug 2020
Robert S. Mills, Jr.Executive officerMar 2018
Aaron S. FletcherDirectorAug 2020
Brian S. WindsorDirectorAug 2020
Glenn S. MattesDirectorAug 2020
Harlan S. WeismanDirectorAug 2020
Malcolm S. FairbairnDirectorAug 2020
Randy S. ThurmanDirectorAug 2020
Robert S. Mills, Jr.DirectorAug 2020
Stephen S. RocamboliDirectorAug 2020